Cancer Vaccine-AAP 2022: Cancer Vaccination and Challenges |
Submission link | https://easychair.org/conferences/?conf=cancervaccineaap2022 |
Abstract registration deadline | August 5, 2022 |
Submission deadline | August 25, 2022 |
About Book:
One of the key components of cancer therapy now includes immunotherapy. In recent years, adoptive cell treatment techniques and checkpoint inhibitors have dominated the field of immunotherapy. However, because checkpoint therapies are only effective in the presence of a preexisting tumor-reactive T-cell response, many patients do not benefit from them. Adoptive cell treatment for solid tumors is also complicated by issues maintaining in vivo activation levels of T cells. To fill this gap, the field of cancer vaccines is currently redeveloping. In fact, the only method that can increase and/or reactivate the population of Type 1 cytokine-oriented tumor-reactive T cells required for tumour management is a vaccine. It is undeniable that therapeutic cancer vaccine development has advanced significantly. The development of rational cancer vaccines has been sparked in the past by a number of scientific breakthroughs, including the discovery of the first human tumour antigen, the selection of peptides by HA, and how this may be utilised to stimulate T cells in vivo. Unfortunately, a number of clinical trials demonstrating only modest efficacy have significantly lowered interest in this type of immunotherapy. Therapeutic cancer vaccines are now again available. The need to activate both CD4 and CD8 T cells, the impact of the hostile tumour micro and macro environments, and new knowledge regarding the regulation of activated T cells drive the development of robust vaccine platforms that can be used in combination treatment strategies to fully maximise their anticancer potential. The first positive results from recent experiments have shown the way forward. The many vaccination platforms, tumour antigens that can be targeted, adjuvants that can be employed, and potential combination methods are just a few of the significant topics covered in this book when it comes to the production of clinically relevant vaccines. For the foreseeable future, the clinical oncologists' scientists and students will use it as a reference book thanks to the perspectives and insights of the subject's well-known experts.
Submission Guidelines
All papers must be original and not simultaneously submitted to another journal or book.
List of Topics
The topics are related to but not limited to the following:
- Role of tumor antigens for cancer vaccine development
- Strategies to develop cancer vaccine
- Advancement and challenges in the development of cancer vaccines
- Combined therapy of cancer with vaccines and chemotherapeutic agent
- Cancer vaccines for lung cancer/ prostate cancer/ breast cancer/pancreatic cancer
- Delivery system for cancer vaccine
- Correlation between cancer vaccine and immunity
- DNA based cancer vaccine: advancement and challenges
- RNA based cancer vaccine: advancement and challenges
- Preventive cancer vaccine
- Utilization of microbial genes as vaccine against cancer
- Roles of various cancer vaccine adjuvants in cancer management
- Survival data and therapeutic outcomes of cancer vaccines
- Tumour immunogenicity and responsiveness towards vaccines
- Utilization of ionic lipid material in the delivery of cancer vaccine
- Utilization of protein and peptides as cancer vaccines: advancement and challenges
- Cancer immunotherapy using mRNA
- Stem cells originated vaccines for cancer therapy
Editors
1. Dr. Rishabha Malviya, Galgotias University, Greater Noida, India.
2. Dr. Bhupendra Prajapati, Ganpat University, Gujarat, India
3. Prof. Sonali Sundram, Galgotias University, Greater Noida, India.
Publication
Cancer Vaccine-AAP 2022 will be published by Apple Academic Press, Taylor and Francis Group.
Important Dates
Abstract Submission
{Approx. 500 Words}: 25th August 2022
Abstract Acceptance Notification: 30th August 2022
Full Chapter Submission: 30th October 2022
Review Notification of Chapter: 10th November 2022
Revised Chapter Submission: 30th November 2022
Contact
All questions about submissions should be emailed to ...Dr. Rishabha Malviya at “editor.rishabha@gmail.com”. (WhatsApp: +91-9450352185)